Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

OHSU researchers study smallpox vaccination protection over time

11.02.2003


Scientists study those vaccinated more than 60 years ago versus one year ago

Oregon Health & Science University researchers are studying the effectiveness of the smallpox vaccine in patients who received inoculations decades ago compared with those vaccinated more recently. The universal belief has been that smallpox vaccinations provide protection for only three to five years. Until now scientists and physicians assumed that anyone vaccinated more than five years ago had little to no protection left. However, researchers at the OHSU Vaccine and Gene Therapy Institute believe that conventional thinking may not be true. To test their theories, scientists are studying how much protection the smallpox vaccination provides 67 years later versus just a year ago. This information may provide a more accurate way of estimating the spread of a potential smallpox outbreak, because nearly 95 percent of Americans older than 35 were vaccinated, and many may still have strong immunity against smallpox.

"I’ve been intrigued about immunological memory for more than a decade. It’s exciting to be able to apply this interest to something that’s relevant to our community right now," said Mark Slifka, Ph.D., assistant professor of molecular microbiology and immunology in the OHSU School of Medicine "We know that people who contract yellow fever, polio, measles or mumps gain a lifelong immunity to those diseases. Now we want to see if this is universally true for other viruses, such as vaccinia, the virus used for immunizing against smallpox."



Vaccinia is a virus contained within the smallpox vaccine and is closely related to smallpox. However, in most cases, vaccinia does not cause serious health problems. The virus promotes smallpox protection by causing the body to produce protective antibodies and white blood cells that can search for and destroy smallpox-infected cells.

Slifka’s lab is collecting blood samples from study participants. These samples are then analyzed to determine the participants’ level of immunity against smallpox. Of the participants that have joined this ongoing study, six people were vaccinated within the last seven years while more than 100 were vaccinated between 15 and 67 years ago. His team is comparing the immunity of both groups to determine whether the vaccine truly loses potency over time.

This study looks at the effectiveness of both arms of the body’s adaptive immune response: antibodies and T-cells. Blood samples from study participants are exposed to vaccina in petri dishes, the same virus used in the smallpox vaccine. If a person has strong immunity against vaccina, then his/her antibodies will neutralize the virus, thus saving healthy cells from becoming infected. If the virus is able to slip past this first line of defense and actually cause an infection, then a strong T-cell response is necessary to destroy virus-infected cells before they multiply and spread.

"In a petri dish, the vaccinia virus is typically very destructive and will eventually kill all of the cells that it encounters. However, if we mix blood serum of a vaccinated person with the virus before it can invade the first cell, then no damage occurs because the cells are protected against infection. Visually, weak immunity against smallpox looks in the petri dish like a lawn with a lot of dead patches of grass, while strong immunity results in a healthy "lawn" that has very few dead patches. With these and other techniques in hand, we can determine who has strong immunity and who has weak immunity following smallpox vaccination." said Slifka.

Scientists are studying the relationship between two levels of protection: protection against the disease and protection against death. The vaccine may prove to provide less protection against disease over time. In other words, a person might still get infected, but vaccination may still provide enough protection to lower the risk of death.

Another standard, but not proven, belief is that three or more vaccinations provide more immunity. Slifka’s team also will look at the effectiveness of multiple vaccinations to determine if several vaccinations do build stronger immunity. Although most participants in this study have been vaccinated only once or twice, there are several volunteers that have been vaccinated between five and 11 times during their lifetimes.

Another research team at the VGTI and OHSU, led by Janko Nikolich-Zugich, M.D., Ph.D., and Mary Stenzel-Poore, Ph.D., is studying immunity to smallpox and vaccinia in people with weaker immune systems, such as the elderly, those on steroid therapy and those under significant stress. Using mice, they hope to discover specific defects in the immune system that prevent these immunocompromised individuals from receiving safe vaccinations against smallpox. Identifying these defects should help them develop re-engineered versions of the smallpox vaccine that can protect these vulnerable populations from this deadly disease. This group also will use Slifka’s results to complement their research and help engineer new vaccines for the vulnerable populations.

Slifka also hopes to work with his co-investigator, Jon Hanifin, M.D., professor emeritus of dermatology in the OHSU School of Medicine, to develop a future study that will look at the weakened immune systems of people with eczema and other skin conditions who were vaccinated years ago, but by today’s standards shouldn’t have been vaccinated.


SPECIFICS:

Mark Slifka, Ph.D., assistant professor of molecular microbiology and immunology in the OHSU School of Medicine; assistant scientist at the OHSU Vaccine and Gene Therapy Institute and the Oregon National Primate Research Center.

Janko Nikolich-Zugich, M.D., Ph.D., professor of molecular microbiology and immunology in the OHSU School of Medicine; senior scientist at the OHSU Vaccine and Gene Therapy Institute and the Oregon National Primate Research Center.

Mary Stenzel-Poore, Ph.D., associate professor of molecular microbiology and immunology in the OHSU School of Medicine.

Jon Hanifin, M.D., professor emeritus of dermatology in the OHSU School of Medicine

Christine Pashley | EurekAlert!

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>